Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Not yet recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 240
- Registration Number
- NCT06905301
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 70
- Registration Number
- NCT06905288
- Locations
- 🇰🇷
Novartis Investigative Site, Busan, Korea, Republic of
Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT06903234
- Locations
- 🇨🇭
Novartis Investigative Site, Basel, Switzerland
A Study of Multiple Sclerosis Routine Clinical Practice: Impact on Adherence and Clinical Outcomes of Ofatumumab Treated Patients
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 155
- Registration Number
- NCT06897657
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.
Recruiting
- Conditions
- Hidradenitis Suppurativa
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT06785675
- Locations
- 🇦🇪
Novartis Investigative Site, Sharjah, United Arab Emirates
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Phase 2
Not yet recruiting
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 420
- Registration Number
- NCT06894511
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
Phase 1
Not yet recruiting
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 228
- Registration Number
- NCT06881823
Pelacarsen Roll-over Extension Program
Phase 3
Not yet recruiting
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT06875973
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Phase 3
Recruiting
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- Biological: Ofatumumab approved doseBiological: Ofatumumab new dose
- First Posted Date
- 2025-03-11
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06869785
- Locations
- 🇺🇸
Elite Clinical Research, Miami, Florida, United States
🇺🇸Fullerton Neuro and Headache Ctr, Fullerton, California, United States
🇺🇸Velocity Clinical Trials, Los Angeles, California, United States
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Phase 3
Not yet recruiting
- Conditions
- Chronic Spontaneous Urticaria (CSU)
- Interventions
- Drug: Remibrutinib matching placeboDrug: Placebo solution for injection
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 400
- Registration Number
- NCT06868212
© Copyright 2025. All Rights Reserved by MedPath